University of North Florida

UNF Digital Commons
UNF Graduate Theses and Dissertations

Student Scholarship

2014

Novel Oral Anticoagulants: Bedrest and Bleeding in Patients
Undergoing Atrial Fibrillation Catheter Ablation
Lynn McWhirter
University of North Florida, n00054097@ospreys.unf.edu

Follow this and additional works at: https://digitalcommons.unf.edu/etd
Part of the Critical Care Nursing Commons, Family Practice Nursing Commons, Life Sciences
Commons, and the Perioperative, Operating Room and Surgical Nursing Commons

Suggested Citation
McWhirter, Lynn, "Novel Oral Anticoagulants: Bedrest and Bleeding in Patients Undergoing Atrial
Fibrillation Catheter Ablation" (2014). UNF Graduate Theses and Dissertations. 520.
https://digitalcommons.unf.edu/etd/520

This Doctoral Project is brought to you for free and open
access by the Student Scholarship at UNF Digital
Commons. It has been accepted for inclusion in UNF
Graduate Theses and Dissertations by an authorized
administrator of UNF Digital Commons. For more
information, please contact Digital Projects.
© 2014 All Rights Reserved

NOVEL ORAL ANTICOAGULANTS: BEDREST AND BLEEDING IN PATIENTS
UNDERGOING ATRIAL FIBRILLATION CATHETER ABLATION
by
Lynn McWhirter

A project submitted to the School of Nursing
in partial fulfillment of the requirements for the degree of
Doctor of Nursing Practice
UNIVERSITY OF NORTH FLORIDA
BROOKS COLLEGE OF HEALTH
August, 2014

Certificate of Approval
The project of Lynn McWhirter is approved:

Michele S. Bednarzyk, Committee Member

Lillia M. Loriz, Committee Member

Kathaleen C. Bloom, Committee Chairperson

Accepted for the Department

Lillia M. Loriz, Director, School of Nursing

Accepted for the College

Pamela S. Chally, Dean, Brooks College of Health

Accepted for the University

John Kantner, Dean of the Graduate School

Date

iii
Dedication & Acknowledgements
I would like to dedicate this to my parents, Henry and Doris McWhirter, whom taught me
the value of education and made me believe that I could accomplish whatever I set out to do. I
would like to acknowledge my family, friends, professional and academic colleagues in
supporting me during my doctorate of nursing practice journey. My husband, Jimmy Neeson,
could not have been more supportive of my efforts in this and my previous academic pursuits.
He has seen me learn to turn on a computer to now completing this project. His extra support,
understanding, love, and encouragement have been appreciated more than he will ever know. My
sister, Gail McWhirter, was the impetus behind my enrollment. I began my doctoral studies
when she was enrolled in her Mental Health NP program, and she has long since graduated and
begun her practice. She never underestimates my abilities and is one of my biggest supporters.
She has been a tremendous sounding board and editor along the way. My coworkers and friends,
Melanie Blair, Michel Hartley, and Karin Prussak have been supportive, understanding, and
collaborative during this process. My supervisor, Leslie Janik, has been enthusiastic, supportive,
and helpful in completing this project and I am very grateful to her. Without the support of my
supervising physicians, Dr. Fred Kusumoto and Dr. Kalpathi Venkatachalam, this project would
not have been feasible. I will be forever grateful for their support of my efforts.
I would be remiss in my dedication if I fail to mention Dr. Kathaleen Bloom, my project
chair. She has guided me through this process and helped me identify clear direction and purpose
along the way. She has allowed me creative freedom, but brought me back to task. I would not
have completed this project without her guidance and suggestions. Dr. Bloom has continued to
keep me motivated and focused throughout the process when I felt as though I could not go
further. I would like to recognize Michele Bednarzyk, my friend and academic mentor, who

iv
served on my committee. She has been there to answer my questions and calm my seas when
necessary. I would also like to acknowledge Barbara Kruger, PhD., Li Loriz, PhD., Gerard
Hogan, DNSc., and Carol Ledbetter, PhD. for their contributions to my educational growth.
Without the support of the nursing faculty at UNF, none of this would have been possible. A
final but heartfelt thanks to all the floor and cath lab nurses, administrators, physicians,
statisticians, librarians, information technologists, and support staff that helped me make this
possible. For all of the people named and unnamed, I am forever grateful for your support of me.

v
Table of Contents
Dedication and Acknowledgements ...................................................................................iii
List of Tables ................................................................................................................... vii
List of Figures ................................................................................................................. viii
Abstract ............................................................................................................................. ix
Introduction .........................................................................................................................1
Overview and Treatment of Atrial Fibrillation ...........................................................2
Overview of Problem...................................................................................................5
Project Purpose ...........................................................................................................6
Definition of Terms.....................................................................................................7
Summary .....................................................................................................................8
Review of Literature ...........................................................................................................9
Sources and Search Process ......................................................................................10
Research Syntheses ...................................................................................................13
Evaluation of Clinical Practice Guidelines ..............................................................18
Theoretical Framework .............................................................................................18
Summary ...................................................................................................................19
Methodology .....................................................................................................................21
Design and Setting ................................................................................................... 21
Sample...................................................................................................................... 22
Procedures .................................................................................................................23
Protection of Human Subjects...................................................................................24
Results ................................................................................................................................25
Participants................................................................................................................25
Outcomes .................................................................................................................26
Summary ...................................................................................................................28
Discussion ..........................................................................................................................29
Relation to other Evidence ........................................................................................29
Limitations ................................................................................................................30
Implications for Practice ...........................................................................................32
Implications for Research .........................................................................................32
Conclusion ................................................................................................................33

vi
Appendices
A: Procedure Checklist ............................................................................................34
B: Patient Measurement Outcomes ..........................................................................36
C: NP Quality Improvement Project Training .........................................................37
D: Nursing Staff Information ...................................................................................38
E: Oral Consent Script .............................................................................................39
F: HIPAA Authorization to Use and Disclose Protected Health Information ....... 40
References .........................................................................................................................42
Vita.....................................................................................................................................46

vii
List of Tables
Table 2.1: Research Synthesis of Bedrest Evidence ........................................................14
Table 2.2: Appraising the Strength and Quality of the Research Evidence ......................16
Table 2.3: Randomized Controlled Trials and Quasi-Experimental Studies of
Bedrest Following Post-femoral Access Procedures .......................................18
Table 4.1: Sample Characteristics by Physician-ordered Bedrest Duration Group .........26
Table 4.2: Primary and Secondary Outcomes by Physician-ordered and Actual
Time in Bed..................................................................................................... 27
Table 4.3: Secondary Outcomes by Physician-Ordered Bedrest
and Actual Time in Bed ................................................................................... 28

viii
List of Figures
Figure 2.1: Flow Diagram of Article Selection Process ...................................................12

ix
Abstract
Atrial fibrillation (AF), the most common cardiac arrhythmia in persons over age 65, is
associated with an increased stroke risk necessitating the need for long-term oral anticoagulation
for risk reduction. With the introduction of direct thrombin and factor Xa inhibitors in the US
since 2010, these novel oral anticoagulants (NOACs) are increasingly being prescribed,
replacing the use of warfarin, a vitamin K antagonist. AF catheter ablation (CA), an elective
procedure requiring femoral vascular access is a treatment for drug refractory and persistent AF.
Bedrest, limb immobilization, and limited head of bed elevation are nursing measures utilized
following femoral venous, and sometimes arterial, sheath removal and hemostasis. Limited
research is available on the appropriate duration of bedrest to minimize bleeding complications
associated with AF ablation in patients who use NOACs. The purpose of this quality
improvement project was to compare and evaluate the effect of bedrest duration on postprocedure bleeding outcomes, urinary complaints, and back pain among patients taking NOACs
while undergoing AFCA.
Thirty patients undergoing elective AFCA on NOACs were orally consented to
participate in the study and placed on shortened (8 hours) or prolonged (>8 hours) bedrest
following vascular hemostasis. Outcome measurements included bleeding after ambulation, back
pain, and urinary complaints. Fifteen patients (50%) were on shortened bedrest and 15 (50%)
were on prolonged bedrest. No statistically significant difference in bleeding, urinary complaints,
or back pain were found. Since there is no clear advantage to prolonged bedrest for patients on
NOACS after an AFCA procedure, clinicians should consider this when deciding on bedrest
duration for their patients.
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Chapter I: Introduction
Atrial fibrillation (AF), irregular rapid contractions of the atria asynchronously from
ventricular contractions, is the most common cardiac arrhythmia. With an estimated prevalence
of 3.4 million persons in 2010, 12 million people are predicted to have the problem by 2050 in
the United States (US) alone (Centers for Disease Control [CDC], 2010; Lloyd-Jones et al.,
2011; Naccarelli, Johnston, Dalal, Lin & Patel, 2012). One-third of hospitalizations are a result
of cardiac arrhythmias, with a 66% reported increase in hospitalizations for AF over the past two
decades. Advancing age, chronic cardiovascular disease, and more diagnoses through outpatient
telemetry monitoring has been cited for the increase in numbers (CDC, 2010; Lloyd-Jones et al.,
2011; Fuster et al., 2006). Treatment of AF represents a significant health care burden to both
patients and healthcare providers. The estimated cost of the treatment of atrial fibrillation of US
patients in 2005 was $6.65 billion per year, including the costs of hospitalization, in- and
outpatient health care, and medications (Coyne, Paramore, Granady, Mercader, Reynolds, &
Zimetbaum, 2006). Hospitalization costs comprise up to 70% of costs spent on treatment of AF
(Gorenek, & Kudaiberdieva, 2013). The estimated average cost in the US is $3600 annually per
patient. The incidence of atrial fibrillation increases with age. The median age for patients with
atrial fibrillation is 66.8 years for men and 74.6 years for women (CDC, 2010).
The mortality rate from AF as either the primary or an underlying cause of death has been
increasing for more than two decades. Thromboembolic (TE) cerebral events and congestive
heart failure (HF) represent two of the most common and costly complications of AF, and are
associated with increased mortality (CDC, 2010). Stroke risk is increased two to seven-fold in
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persons with AF with an annual ischemic stroke risk of approximately five percent annually. AF
may cause up to 15 to 20 % of ischemic strokes in the U.S. and increases one’s risk by five times
(CDC, 2010; Fang et al., 2008).
Thrombus formation in AF, attributed to low flow, or stasis of atrial blood, most often
accumulated in the left atrial appendage, is associated with cerebral TEs in AF. Known atrial
stunning and stasis occurs with cardioversion from AF to sinus rhythm (SR), whether
spontaneous, chemical or electrical (Fuster et al, 2006). Progressive improvement of atrial
stunning usually occurs with conversion over days to several weeks, and varies in intensity based
on severity of heart disease and duration of AF. This thrombus accumulation propensity with AF
is the cornerstone of the stroke risk and need management with antithrombotics.
Treatment of Atrial Fibrillation
Treatment of AF is predicated on symptom management, prevention of TE, and restoring
a normal rhythm (Fuster et al., 2006). Standard treatment options of AF include rate control and
rhythm control strategies including anti-arrhythmic drug therapy (AAD), and direct current
cardioversion (DCC). Atrial fibrillation catheter ablation (AFCA) has emerged over the last
decade as a viable rhythm control treatment option, usually as a second line treatment when
failure has occurred and the individual is considered drug refractory AF (Calkins & Dewire,
2013).
Anticoagulation
Persons with diagnosed nonvalvular AF are administered oral anticoagulants (OAC) for
thromboprophylaxis. Historically, OAC therapy has been limited to warfarin, a vitamin K
antagonist (VKA) with many unfavorable qualities and limitations including food-food and fooddrug interactions, a narrow therapeutic index, slow onset of action, a long half-life, major
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bleeding, and the need for routine laboratory blood testing and monitoring of a patient's
international normalized ration (INR) blood level for dose titration. For these reasons, many
patients have difficulty with maintaining a time in therapeutic range (TTR) and are at increased
stroke risk in AF despite taking an OAC (Camm et al, 2012; Fuster et al., 2011; Maan et al.,
2012). Since the Food and Drug Administration (FDA) approval of dabigatran etexilate, a direct
thrombin inhibitor, the options for OAC have exploded, and the agents are termed novel oral
anticoagulants (NOAC).
Dabigatran was the first new OAC available in more than 50 years. As of this writing,
rivaroxaban and apixaban, oral direct Factor Xa inhibitors, have also received FDA approval in
the U.S. for stroke prevention in nonvalvular AF. Like dabigatran, the Factor Xa inhibitor
NOACs entered the marketplace following the release of several head-to-head trials of warfarin
and the NOACs in which they were found to be more efficacious in stroke and systemic embolic
prevention, carry a lower risk of intracranial bleeding, and have a favorable safety profile in AF
patients (Miller, Grandi, Shimony, Filion, & Eisenberg, 2012). In 2012, the European Society of
Cardiology (ESC) updated their 2010 guidelines for atrial fibrillation, concluding that NOACs
offer better efficacy, safety, and convenience compared to OAC with VKA's. Thus,
where an OAC is recommended, one of the NOACs-either a direct thrombin inhibitor
(dabigatran) or an oral factor Xa inhibitor (rivaroxaban, apixaban), should be considered
instead of adjusted dose VKA (INR 2-3) for most patients with AF. (Camm et al., 2012,
p. 2731)
There was no recommendation for one of the NOACs over another due to insufficient evidence.
With the advent of NOACs, patients and providers have alternative options. Because
NOACs offer a more predictable pharmacokinetic profile than that of warfarin, there is no need
for monitoring the INR level and adjusting the dose to achieve a target range, making this a more
acceptable therapy. Evolutionary changes in stroke risk prophylaxis for AF with these NOACs
offer patients many options to choose from based on personal preferences and risk profiles. The
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NOACs do not have a safe and acceptable antidote, unlike warfarin. This elicits fear and
uncertainty in the event of major bleeding. For these reasons, many practitioners and patients are
slow and cautious when transitioning to their use. Ongoing safety and efficacy research will need
to guide clinical practice. With many AF patients now taking NOACs, preventive and effective
management of bleeding complications and inquiries are necessary of the providers to stay
abreast of evolving issues related to NOAC use as it becomes available.
Pharmacologic therapy
Either a rate or rhythm control strategy is acceptable treatment of symptomatic AF, and
has similar mortality outcomes (Wyse et al., 2002). Rate control is attained with beta-blockers,
nondihydropyridine calcium channel antagonists, digitalis, alone or in combination with
amiodarone. Rhythm control strategies for pharmacologic cardioversion or maintenance of sinus
rhythm (SR) may include flecainide, dofetilide, propafenone, and ibutilide. Quinidine or
procainamide administration may be considered but the usefulness is not well established.
Digoxin and sotalol are not recommended for pharmacological cardioversion. Hospital
admission and monitoring is required for initiation of quinidine, procainamide, disopyramide,
and dofetilide for pharmacological cardioversion from AF to SR (Fuster et al., 2006).
Catheter ablation
Catheter-based atrial fibrillation ablation, which began in the late 1980's, is now one of
the most performed ablation procedures in large US hospitals (Calkins & Dewire, 2013). The
procedure is performed in the laboratory under anesthesia sedation. With ablation catheters and
mapping systems, the goal of AFCA is eradication of AF through pulmonary vein isolation (PVI)
using radiofrequency or cryoablation of the AF pathways. Vascular access is obtained via the
femoral vein with adjuvant femoral artery monitoring in some cases. The femoral sheaths are
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removed following the procedure in a recovery holding area when the physician and staff deem
the patient hemodynamically stable with an acceptable activated clotting time. Achieving groin
hemostasis is traditionally performed by manual compression and use of FemoStop compression
devices. The patient is confined to bed for a specified time period with immobilization of the
affected extremities for management of vascular access bleeding complications. Further patient
activity restrictions include head of bed (HOB) limitations and use of indwelling urinary
catheters in lieu of bathroom privileges.
AFCA risks include pericardial effusion, vascular access complications requiring surgery
or blood transfusion, cardiac tamponade, hemothorax, stroke, sepsis, pneumonia, phrenic nerve
injury and paralysis, esophageal injury, atrio-esophageal fistula, PV stenosis, radiation exposure,
acute coronary artery occlusion, periesophageal vagal injury, mitral valve trauma, post
procedural arrhythmias (Calkins et al., 2007). The rate of complications varies based on many
factors with bleeding related complications the most common. Anticoagulation further
compounds the bleeding issue, as it is necessary to prevent stroke. Bleeding complications may
be compounded due to need for aggressive intraprocedural anticoagulation with intravenous (IV)
unfractionated heparin to minimize catheter clotting and thromboembolic events. With
additional use of NOACs, and their lack of a reliable antidote, bleeding complications are
increasingly worrisome for patients and providers.
Overview of the Problem
Bleeding complications are long recognized and associated with femoral vascular access
in percutaneous cardiac procedures including catheter ablation, coronary angiography, and
percutaneous coronary interventions (PCI) (Merriweather & Suzbach-Hoke, 2012; Mohammady,
Heidari, Sari, Zolfaghari, & Janani, 2013; Prudente et al., 2009; Raviele et al., 2012). Bedrest,
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compression, and lower extremity immobilization are commonly used nursing management tools
to maintain femoral access hemostasis and minimize complications of bleeding. Femoral
vascular access bleeding complications will manifest as bruising, hematoma, pseudoaneurysm,
and arteriovenous fistula. More serious and life threatening complications of cardiac tamponade
and hemothorax may also occur rarely. Complications can lead to longer hospitalizations,
surgical procedures, and increased costs (Raviele et al, 2012, Shoulders-Odom, 2006).
Early ambulation of patients post-cardiac catheterization and PCI is widely recognized to
be associated with fewer adverse outcomes which may include deep vein thrombosis, back pain,
difficulties with eating, drinking, and voiding, and overall patient dissatisfaction (Schiks et al.,
2008). Post-PCI or AFCA bedrest may vary from 4 to 18 hours after femoral access sheath
removal, with patients taking anticoagulants. Both groups of patients undergo anticoagulation in
conjunction with their respective cardiac procedures and are cared for by the same nursing staff.
No consistency or evidence exists on the optimal time to minimize bleeding risk and decrease
adverse outcomes of prolonged bedrest. Very limited, to no research, is available on postoperative bedrest recommendations to mitigate bleeding complications in the post-AFCA patient
population on NOACs.
Purpose of Project
The project purpose was to evaluate primary and secondary outcomes based on the
duration of bedrest in patients undergoing AFCA on NOACs. Primary outcome measurements
will include bleeding complications: bruising, hematoma formation, pseudoaneurysm and
arteriovenous fistula formation. Secondary outcomes will include urinary complaints including
need for catheterization, hematuria, frequency, urgency, and back pain while on bedrest. The
goal of this project was to explore bedrest duration effects in order to minimize the patient
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discomfort of prolonged bedrest and urinary catheters, standardize the postoperative care of
AFCA patients on NOACs, while maintaining safe practice through implementation of a
standardized post-procedural protocol for bedrest and activity restrictions in patients on NOACs.
Definitions
Atrial fibrillation
For the purposes of this project, AF was defined as paroxysmal or persistent in character
as classified in ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial
Fibrillation (Fuster et al., 2006).
Anticoagulation
For the purposes of this project, anticoagulation refers to both oral and IV
antithrombotics, but did not include antiplatelet medications such as clopidogrel or aspirin.
Bleeding Complication
A bleeding complication was measured as bleeding requiring reapplication of manual
pressure and/or pressure dressing or device, a hematoma larger than 5 centimeter (cm) in width,
or blood loss requiring transfusion, additional bedrest, additional testing, or increased length of
hospital stay.
Shortened Bedrest
For the purposes of this project, shortened bedrest was eight hours or less.
Prolonged Bedrest
For the purposes of this project, prolonged bedrest was greater than eight hours.
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Urinary Discomfort
For purposes of this project, urinary discomfort was defined as difficulty with urination
requiring reinsertion of catheterization, patient reported burning or bleeding with urination.
Back Pain
For purposes of this project, back pain was assessed by nursing with the widely used 1 to
10 point pain scale, and will be classified as mild (0-3), moderate (4-6), or severe (7-10).
Summary
Atrial fibrillation and management with CA is growing exponentially as patients seek
curative treatment of the highly prevalent condition. With the attractiveness and favorable
outcomes of NOACs for ease of use in stroke risk reduction, evidence based care of these
patients is necessary for optimal outcomes. AFCA, like percutaneous transfemoral coronary
interventions, requires femoral vascular access and sheath removal, maintenance of hemostasis,
and management of bleeding complications. While research abounds on optimal time for bedrest
and early ambulation in the cardiac catheterization and PCI patient population, very little is
available on the newer AFCA patient needs. This project will evaluate the bleeding outcomes of
varying post-procedural bed rest times in AFCA patients taking NOACs, in hopes of adding to
the limited body of knowledge currently available in this arena.
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Chapter 2: Literature Review
A brief overview of the bedrest literature is followed by a description of the search
strategies and criteria employed to determine the use of bedrest and immobilization in prevention
of bleeding complications following femoral vascular access in cardiac procedures. This is
followed by a synthesis of the evidence and implications for the direction of the project.
Bedrest Following Procedures Requiring Femoral Vascular Access
Although bedrest and affected lower limb immobilization is the accepted practice
following invasive femoral artery and vein access procedures following sheath removal and
hemostasis, prolonged bedrest and immobilization have been cited with increased patient
dissatisfaction, back pain, and difficulty with urination with resultant urinary catheterizations
(Merriweather & Suzbach-Hoke, 2012; Shoulders-Odom, 2006). The existing cardiac
catheterization laboratory guidelines addressing bedrest duration are abbreviated and general,
lacking in specificity. Sheath size is the major determinant of bedrest duration and commonly
ranges from 1 to 2 hours for 4 and 5 French (F) sheaths, and 2 to 4 hours for 6 to 8 F sizes
(Bashore et al., 2012). It is understood that certain patient traits including obesity, female
gender, and uncontrolled hypertension may place an individual at increased bleeding risk
following procedures requiring femoral vascular access. Further activities that may increase
bleeding risk are OAC use, bleeding tendencies, coughing, vomiting, straining with elimination,
difficult vascular access, multiple femoral vascular procedures, larger sheath sizes, operator
experience, hemostasis techniques, use of vascular closure devices, and longer duration of
sheaths (Baman et al., 2011). Despite the lack of hard evidence for extended bedrest, varying
bedrest duration exists in practice.
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Very little research is available on the appropriate amount and role of bedrest duration in
avoidance of bleeding complications in the AFCA population. However, there is a substantial
body of evidence, including meta-analyses, randomized clinical trials (RCTs), and systematic
reviews, on other diagnostic and therapeutic procedures requiring femoral access, including
diagnostic cardiac catheterization (DCC), percutaneous coronary intervention (PCI), and
percutaneous transluminal coronary angiogram (PTCA). Thus, the evidence-base for this project
is post-procedure bedrest duration of patients undergoing DCC, PTCA, and PCI.
Search Strategies
The search strategy was driven by the following PICO question: In patients on NOACs
who undergo femoral access procedures, does prolonged bedrest improve outcomes and
satisfaction with care?
P (population): Patients taking NOACs
I (interest): Prolonged post-procedure bedrest (12 hours or longer)
C (comparison): Traditional post-procedure bedrest (<8 hours)
O (outcome): Bleeding complications, hematoma, AVF, pseudoaneurysm, back pain,
urinary complaints, patient satisfaction
CINAHL, PubMed, and the Cochrane Library databases were searched using various
combinations of keywords including femoral vascular access, catheter ablation, cardiac
catheteriz(s)ation, bedrest, ambulation, bleeding, hematoma, anticoagulation, electrophysiology
study, and atrial fibrillation. On initial searches all dates and study types were searched, then
narrowed down to include the past five years, 2008 to 2013, with English language the only limit
selected. Further limited searches including searching for randomized controlled trials (RCTs),
meta-analyses, and systematic review articles and manually reviewing the reference lists of
selected high quality studies.
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Upon review of articles regarding bedrest and bleeding complications following femoral
vascular access for DCC, PTCA, PCI, and EP studies, the author excluded DCC studies from
synthesis, due to the simplicity of the procedure compared to the more involved PTCA, PCI, or
electrophysiology study (EPS) or AFCA. The DCC typically uses a smaller vascular access
sheath or catheter size (4 French [F] or 6 F), and is of shorter duration than when a patient
receives an intervention of balloon angioplasty in PTCA, or stent deployment in PCI. In the
PTCA and PCI patients, the larger sheath and catheter sizes required for vascular access and
intervention, and procedure duration are more akin to the complex EPS and AFCA procedures.
The included studies for synthesis examined outcomes of femoral access site bleeding and
hematoma, patient comfort, and some included urinary discomfort as a secondary outcome
related to bedrest duration or ambulation time. Figure 1 depicts the flow of the literature search.
Literature Synthesis
Seminal research on the role of bedrest duration consisted of a series of four time-in-bed
studies (TIBS). The first two studies were done with patients undergoing DCC, first reducing
bedrest duration from 12 to 6 hours (Keeling, Knight, Taylor, & Nordt, 1994), then, reducing
time-in-bed from 6 to 4 hours (Keeling, Taylor, Nordt, Powers, Fisher, 1996). These studies
supported evidence that shorter time-in-bed following DCC was not associated with an increased
risk of bleeding. Patient satisfaction was also improved with shorter post-DCC time-in-bed.
Similar results were found with later studies with patients undergoing PTCA and reduced bedrest
from 6 to 4 hours (Keeling, Fisher, Haugh, Powers, Turner, 2000) and patients undergoing EPS
with reduced bedrest from 4 to 2 hours (Gianakos, Keeling, Haines & Haugh, 2004).
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Literature Search Databases: CINAHL,
PubMed, Cochrane Library

Search results combined after
duplicates removed (n = 1048)

Articles screened by
title and abstract

Excluded (n = 1029 )
Reason 1: No bedrest or
activity outcome
Reason 2: Bleeding outcome
not included
Reason 3: Evaluation of
vascular closure device

Reason 4: Pregnancy

Included for manuscript
review (n = 19)

Manuscript review and
application of inclusion
criteria

Studies included for
synthesis
(n = 13)

Figure 2.1. Flow diagram of article selection process.

Excluded (n = 6)
Reason 1: Use of vascular
closure device
2: Independent variable
of bedrest duration not
measured
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Research syntheses
Since these seminal studies, a plethora of research has been done in this area. Much of the
research has been synthesized in several meta-analyses and systematic reviews (see Table 2.1).
Three recent meta-analyses of a total of 40 RCTs on shortened bedrest duration following
femoral sheath removal in 10,658 patients undergoing DCC or PCI procedures found no effect
on bleeding or hematoma formation (Kim et al., 2013; Mohammady Heidari, Sari, Zolfaghari, &
Janani, 2013; Tongsai & Thamlikitkul, 2012). These findings echoed those of three earlier
systematic reviews of experimental, quasi-experimental, and descriptive studies (Chair et al.,
2008; Reynolds, Waterhouse, & Miller, 2001; Vaught & Ostrow, 2001).
Experimental and Quasi-experimental Studies
Ongoing research continues to provide evidence of the safety of early ambulation. A total
of nine studies were reviewed and synthesized (see Table 2.2). Table 2.3 provides the criteria
used to determine the strength and quality of the evidence.
Similar to the previous research syntheses, there was no difference in bleeding or
vascular complications with shortened bedrest duration. In one instance, there was a nonsignificant increase in bleeding in the longer bedrest (Tagney & Lackie, 2005). There was no
difference in urinary complaints or back pain among the groups. Patient satisfaction was not
specific to bedrest duration in the included study.
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Table 2.1
Research Syntheses of Bedrest Evidence
Author
(Year)
Kim et al.
(2013)

Method

Sample

Intervention

Outcome Measurement

Conclusions

Meta-analysis

15 RCTs or quasiexperimental studies with
4,785 pts undergoing PCI

Early ambulation

Systematic
review and
meta-analysis

20 RCT's or quasiexperimental studies with
4019 pts undergoing DCC

Different durations (224 h) of bedrest before
ambulation

Vascular complications:
hematoma formation and
hemorrhage at puncture
site
Vascular complications
Pain
Urinary discomfort
Patient satisfaction;

Tongsai &
Thamlikitkul(
2012)

Meta-analysis

5 RCTs with 1,854 pts
undergoing PCI

Early ambulation (24H vs Late
ambulation (6-10h):

Vascular complications:
bleeding, hematoma

Chair et al.
(2008)

Systematic
review

18 RCTs or quasiexperimental studies with
4,294 pts undergoing
DCC

Varying bedrest
duration

Vascular complications:
bleeding, hematoma,
bruising, pseudoaneurysm
Back pain
Groin pain
Urinary discomfort
Patient satisfaction

No increase in RR ratio of the
incidence of hematoma formation nor
bleeding at the puncture site based on
early ambulaiton
Early ambulation (2-3h) had no
significant effect on incidence of
vascular complications (hematomas
reported 7.6% (268 occurrences) and
bleeding 2.2% (47 occurrences);
back pain was lower in shorter
bedrest; decreased urinary discomfort
at 4h compared to 12-24 h (mean
difference: -1.48: 95% CI: -2.37,0.59)
Pooled RR of hematoma was 0.82
(95% CI, 0.53-1.28);
Pooled RR of bleeding was 1.77(95%
CI, 0.87-3.59)
Early ambulation after PCI was not
associated with an increased risk of
hematoma or bleeding and comfired
the findings of earlier studies
recommending reduced time in bed
following sheath removal from 6-10h
to 2-4h
No benefit related to bleeding and
hematoma in longer than 3h bedrest;
Less back pain in groups <6h bedrest;
Methodological deficiencies in
evidence base for generalizability of
studies; Standardized, validated tool
needed for hematoma measurement;

Mohammady
et al. (2013)
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Author
(Year)
Reynolds et al.
(2001)

Method

Sample

Intervention

Outcome Measurement

Conclusions

Systematic
review

Early ambulation;

Vascular complications:
bleeding, hematoma
Pain, comfort,
Patient satisfaction

Little existing evidence based research
existing; Further large scale studies
studies to guide post-PTCA on HOB
elevation, walking, and patient
comfort

Vaught &
Ostrow (2001)

Systematic
review

8 experimental, quasiexperimental, and
descriptive, studies with
1,352 pts undergoing
PTCA
1 survey of 100 hospitals
5 experimental, quaisexperimental, and
descriptive studies of 235
pts undergoing PTCA
1 survey of 70 hospitals

Bedrest duration

Vascular complications:
bleeding, hematoma
Pain
Patient satisfaction

Decrease in hours of bedrest is safe
following PTCA; more research is
needed on specific post-procedure
interventions and research articles
needed on protocols; reliable and
valid tool to measure bleeding and
hematoma formation; universal pain
scale needed;
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Table 2.2
Randomized Controlled Trials and Quasi-experimental Studies of Bedrest Post Femoral Access Procedure
Author
Intervention/
Method
Sample
Outcomes and Measures
(Year)
Control
Chair et
RCT-single
Pts undergoing DCC
IG = 4h bedrest
Vascular complications
al. (2012) blinded
with unknown sheath
CG = 12-24h bedrest
size
Pain
IG: n= 63
CG: n= 74
Urinary discomfort

Gianakos
et al.
(2004)

RCT

Keeling et
al. (1994)

RCT

Keeling et
al. (1996)

RCT

Pts undergoing EP
with 8F or smaller
sheath
IG: n=31
CG: n= 37

Pts undergoing DCC
with unknown sheath
size
Pts undergoing DCC
with unknown sheath
size

IG = 2h bedrest
CG = 4h bedrest

Patient satisfaction
Bleeding

Results
1 pt in CG with bleeding
Less back pain at 8 hours for
IG (OR=0.19, 95% CI,
0.08-0.45, p<0.001);
Less "very or unbearable
urination discomfort" in IG
than CG (OR=0.35, 95% CI,
0.14-0.90, p=0.03)
Patient satisfaction no
difference
No difference in bleeding
incidence among groups

Back pain

Back pain in 2 pts in CG and
1 pt in IG

Patient satisfaction

Patient satisfaction findings
unclear as pts rated overall
care and not specific to
bedrest duration
No difference in bleeding
incidence among groups

IG = 6h bedrest
CG = 12 h bedrest

Bleeding

IG = 4h bedrest
CG = 6h bedrest

Bleeding

Quality of
Evidence
Level I B

No difference in bleeding
among the groups

Level II C

Level II C
Level II C
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Author
(Year)
Keeling et
al. (2000)

Method
RCT

Sample
Pts undergoing PTCA
with 8F catheter
primarily

Intervention/
Control
IG = 4h bedrest
CG = 6h bedrest

Outcomes and Measures
Bleeding

98% of pts did not bleed;
Bleeding was associated
with higher ACT and reprocedures

IG bleeding in 28 (4%);
CG bleeding in 26 (4%);
IG bruise at 1 wk- 464
(74%);
CG bruise at 1 wk-438
(73%);
Late hematoma formation
less in IG (p<0.001) and no
increase in early bleeds or
hematoma formation
9 puncture site complications
in IG (2.7%) and 6 in CG
(3.0%) p=0.002;

IG: n=51
CG: n= 20
Searle &
Hoff
(2000)

Quasiexperimental

Pts undergoing DCC
with unknown sheath
size
IG: n= 680
CG: n=696

IG = 2h bedrest
CG = 3h bedrest

Bleeding or hematoma at
discharge and 1 week post

Schiks et
al. (2008)

Quasiexperimental

Patients undergoing
PCI or fractional flow
reserve (FFR) with 6F
sheath
IG: n= 329
CG: n = 202

IG = 4h bedrest
CG = 10h bedrest

Puncture site complications:
hematoma, bleeding,
pseudoaneurysm, AVF

Patients undergoing
DCC or PTCA with 6F
sheath size
IG: n = 176
CG: n = 195

IG = 3h bedrest
CG = 6h bedrest

Tagney &
Lackie
(2005)

RCT

Results

Patient comfort
Bleeding

Hematoma

Patient comfort not
statistically significantly
different in groups
Bleeding complications
increased from 5(2.6%) in
CG to 11(6.3%) in IG-not
statistically significant
(p=o.333);
Hematomas: 29 (14.8%) in
IG; 19 (10.8%) in CG;

Quality of
Evidence
Level II C

Level III B

Level II A

Level I B
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Table 2.3
Appraising the Strength and Quality of the Research Evidence
Strength of Research Evidence Rating Scheme
Level
I

Type of Evidence

II

Evidence obtained from an experimental study/randomized controlled trial (RCT) or
meta-analysis of RCTs
Evidence obtained from a quasi-experimental study (cohort study)

III

Evidence obtained from a non-experimental study, qualitative study, or meta-synthesis

Quality Rating Scheme for Research Evidence
Grade

Research Evidence

A = High
B = Good
C = Low
Major Flaws

Consistent results with sufficient sample, adequate control, and definitive conclusions;
consistent recommendations based on extensive literature review that includes
thoughtful reference to scientific evidence
Reasonably consistent results; sufficient sample, some control, with fairly definitive
conclusions; reasonably consistent recommendations based on fairly comprehensive
literature review that includes some reference to scientific evidence
Little evidence with inconsistent results; insufficient sample size; conclusions cannot be
drawn

Note. From Johns Hopkins nursing evidence-based practice model and guidelines p. 90, by R.P.
Newhouse, S.L. Dearholt, S.S. Poe, L.C. Pugh, & K.M. White, 2007. Indianapolis, IN: Sigma
Theta Tau International.
Clinical Guidelines
Nursing clinical guidelines by Rolley, Salamonson, Wensley, Dennison, and Davidson
(2010) in Australia address peri-procedural care of PCI patients. Although no clear bedrest
duration was recommended in the guidelines, times from 2 hours to 4 hours were graded as a "D"
recommendation, meaning evidence is weak and recommendations should be applied with
caution. Consensus was based on expert opinion only.
Theoretical Framework
The studies synthesized for this literature review cite patient comfort and safety as
primary endpoints but none clearly delineate a theoretical framework. Im and Meleis (1999)
discussed the disconnect clinicians may feel between grand theories and actual clinical practice
of nursing and the need for scholars to consider the increasing patient complexity, diversity and
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multiple factor complications. Situation specific theories are defined as theories "that focus on
specific nursing phenomena that reflect clinical practice and that are limited to specific
populations or to particular field of practice" (Im & Meleis, 1999, p. 13). This approach to
developing a situation-specific theory easily translates to care of the AFCA patient and the
dynamic nature of evolving knowledge of post procedure bedrest and application of this growing
evidence. With the emergence and increasing use of NOACs coupled with the growing practice
of AFCA, a clinically specific nursing theory is appropriate for use. The situation-specific theory
is put in social and historical context, which clearly is in line with the practice needs of nursing
caring for this patient population. Bedrest duration has evolved and shortened in DCC and PCI
patients and will continue to evolve in AFCA patients as further research and investigations are
performed. A clear connection between research and practice is present in situation-specific
theories, and this will be necessary to build the body of knowledge for the appropriate bedrest
duration for AFCA on NOACs. Patient diversity and individual traits will limit generalizability
of all findings of appropriate bedrest duration as the authors propose in a situation-specific
theory (Im & Meleis, 1999).
Summary
Although though there is no evidence to date regarding duration of bedrest post-AFCA
and either complications or patient satisfaction, there is compelling evidence regarding other
femoral vascular access procedures. Because of the similarities in the procedures themselves
with respects to vascular access as well as in the post-procedure precautions, it is reasonable to
conclude that the same would be true of the outcomes with respect to bedrest. Evidence
supporting NOACs in AFCA with safety and efficacy in the periprocedural time is surfacing,
there is a tremendous need to give nursing the tools to care for these patients. As AFCA
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becomes more widely performed on patients taking NOACs, literature regarding best nursing
practice is crucial to provide high quality patient care. Minimizing patient discomfort including
back pain and urinary issues, and safely managing femoral vascular access site complications is
tantamount to best nursing practice. This project examines ongoing bedrest practices as a risk
factor for complications and satisfaction in patients undergoing invasive femoral venous and
arterial access in AFCA while taking NOACs.
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Chapter III: Methods
This chapter includes a description of the design setting and sample used in this quality
improvement project. This is followed by a discussion of data collection procedures and issues
related to the protection of human subjects.
Design
This was a quality improvement (QI) project evaluating primary and secondary outcomes
based on the duration of bedrest in patients who have undergone atrial fibrillation catheter
ablation while on novel oral anticoagulants.
Setting
The setting for this project was a 249-bed teaching hospital in the southeastern United
States. Approximately 15 to 20 patients undergo elective AFCA procedures each month, of
which approximately 60% are taking NOACs. The procedures are performed by two
electrophysiologists. Immediate post procedure care occurs in a 10 bed holding bay of the
cardiac catheterization lab with subsequent transfer to a 23 bed telemetry unit with a 1 to 4 nurse
to patient ratio for overnight observation.
Current Practice
Immediately following the procedure, patients are in the post-op holding area while they
awaken from anesthesia and undergo sheath removal and manual compression to achieve
hemostasis. Post-procedure care is carried out according to standard hospital protocols as
directed by individual physician orders. After manual compression and hemostasis is attained, a
FemoStop compression device is applied to the groin with 80mm Hg inflation and 10mmHg
reduction hourly over 8 hours (see Appendix A). The duration of bedrest depends on the
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physician performing the procedure. Physican A allows his patients to ambulate at the time of
FemoStop® deflation and removal. Physician B requires an additional 4 hours of bedrest before
ambulation.
Nurse practitioners (NPs) are in-house overnight and are the primary providers as first
call during the patient's observation status following the procedure after receiving sign out from
the physician. The role of the NP includes entering post-procedure orders, ordering home
medications, performing assessments of the puncture site, treating pain, monitoring for bleeding
and urinary complaints, and performing the discharge the following morning. The physician
rounds on the patient the following morning and issues are generally discussed at that time
The details of the AFCA procedure are recorded on a standard EP Pre/Post Checklist that
is not a permanent part of the patient's medical record (see Appendix A). This checklist includes
the procedure and the name of the physician performing it, medical history, height, weight, lab
results, OAC and when last taken, intraoperative medications and anticoagulants administered.
The sheath sizes and locations and times of hemostasis are recorded with ambulation time.
Further information recorded on this sheet includes the vital signs, groin/site checks, bleeding
complications, FemoStop management, and pulses. This sheet is used by nursing staff to
transition care from the post-op holding area to the telemetry unit where the patient will stay
overnight.
Sample
A convenience sample of 30 patients taking NOACs and undergoing AFCA between
February 3, 2014 and April 30, 2014 was collected for analysis. Exclusion criteria included
difficult vascular access in the EP lab or significant rebleeding requiring additional manual
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compression with sheath removal in the holding bay prior to transfer to the nursing unit. All
patients undergoing AFCA on NOACs were eligible for inclusion.
Procedures
This quality improvement project did not affect the routine post-procedure care of patients
undergoing AFCA. Enrollment of patients took place either pre- or post-operatively in the cath
lab holding bay or the patient room. This was determined based on scheduling and flow of
patients. An oral consent and signed authorization to access private health information was
obtained by either the PI or co-investigator authorized to do so. EP Pre/Post Checklists were
collected at the time of discharge by the nurse practitioner and deidentified by the principle
investigator (PI) prior to data entry. Each record was assigned a participant code number at that
time. Additional information collected by the NP the morning following the procedure using the
Post-EP Procedure Assessment and using the same participant code number (see Appendix B).
The recorded information included time of ambulation, bleeding complications, and patient
complaints of urinary discomfort or back pain.
Final assessment of bleeding outcome and presence of a hematoma was evaluated by
direct visualization, palpation, and auscultation of the groin puncture sites after removal of all
dressings by the NP. Nursing staff notified NP's during the night if bleeding occurred with first
ambulation or was noted with groin checks. The patients' urinary complaints and back pain was
evaluated by questioning of patient and nurse at time of NP discharge visit the following
morning. Urinary complaints included burning, difficulty with urinating on bedpan, and inability
to void requiring urinary catheterization. Back pain was evaluated by the use of pain medication
and patient verbalization of complaints of back pain. Bedrest duration following hemostasis was
recorded by the nursing staff or NP at time of collection of data sheets on morning of discharge.
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The patients on the shortened bedrest track often remained in bed for a prolonged time, not only
for bleeding reasons. These data were routine data already collected during routine postprocedure assessment and patient care prior to discharge.
The staff collecting the data was trained by the PI to ensure the completion and retention
of the data collection sheets (see Appendix C). Frequent reminders to ask these questions at time
of patient discharge and assist in data collection was provided to the NP team involved in this
role through flyers (see Appendix D) and verbal cues as well as the posting and distribution of
the Post EP Procedure Assessment form in the cath lab holding area, the NP office, and the
nursing unit where care for these patients was provided. These questions of the patient were
routine questions of current practice by both nursing staff and NPs when discharging the patient.
Protection of Human Subjects and Ethical Considerations
Application to the institutional review board (IRB) was performed and approval was
obtained for minimal risk status for one year. Only deidentified data was collected prospectively
with no change in usual care practices. The hospital served as the authorized IRB of record for
the University of North Florida (UNF) IRB approval. Patients provided an oral consent to
participate in the study (see Appendix E) and signed and received a copy for permission to allow
investigators access to their personal health information (see Appendix F).
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Chapter IV: Results
This chapter includes a description of the sample and delineation of the sample
characteristics. This is followed by an overview of the results with respect to primary and
secondary outcomes related to duration of bedrest.
Sample Characteristics
A total of 30 patients underwent atrial fibrillation catheter ablation while on novel oral
anticoagulants during the study period. Thirty (100%) were invited to participate in the study and
30 (100%) consented. Participants ranged in age from 45 to 77 (M =66.5; SD = 6.7). Body mass
index ranged from 23.2 to 39.2 (M = 30.7; SD = 5.3). The actual time in bed ranged from 6 hours
and 9 minutes to 16 hours and 40 minutes (M = 10 hours and 6 minutes, SD = 3 hours, 18
minutes). The majority of the participants were males taking rivaroxaban as their NOAC.
Twenty-two patients (73.3%) were placed on the shortened bedrest track of 8 hours as
ordered by the physician, and 8 (26.7%) were on prolonged bedrest ordered for 12 hours. These
orders were placed based on physician preference. Because of a variety of factors, the actual
length of time in bed varied within both groups. The actual time in bed exceeded the ordered
times due to NP, nursing or patient preferences, time that the procedure was completed, and
sleeping through the time allowed for ambulation. Thus, 15 patients (50%) were actually on
shortened bedrest (≤ 8 hours) and 15 (50%) were on prolonged bedrest (> 8 hours). See Table 4.1
for a description of sample characteristics by actual bedrest duration.
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Table 4.1
Sample Characteristics by Actual Bedrest Duration Group
Characteristic
Gender
Male (N = 23)
Female (N = 7)
NOAC
Rivaroxaban (N = 14)
Apixaban (N = 9)
Dabigatran (N = 7)

Shortened Bedrest
< 8 hours
N = 22
73%

Prolonged Bedrest
> 8 hours
N=8
27%

17
5

77%
23%

6
2

75%
25%

11
6
5

50%
27%
23%

3
3
2

37.5%
37.5%
25%

Outcomes
Primary Outcomes
Primary outcome data were analyzed according to both physician-ordered bedrest
duration groups and actual time in bed (see Table 4.2). There were 5 cases of bleeding after
ambulation requiring additional bedrest and manual compression. The bleeding occurred in 5
patients: 3 patients in the shortened bedrest track and 2 patients in the prolonged bedrest track.
One patient in the shortened bedrest track had a post-operative hematoma from an inadvertent
arterial puncture and required additional testing of complete blood count (CBC), but suffered no
re-bleeding with shortened ambulation. Of the 5 patients that bled, only 1 was in bed for eight
hours or less, and the remaining 4 had bedrest durations exceeding 8 hours (M = 10.6; SD= 3.6)
due to the bleeding or reported “oozing.” Two patients from the short track had FemoStop
reapplication with additional bedrest.
Secondary Outcomes
Secondary outcome data were analyzed according to ordered and actual bedrest duration
groups (see Table 4.3). Secondary outcome measurements included urinary complaints of
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Table 4.2
Primary Outcomes by Physician-Ordered Bedrest and Actual Time in Bed
Complication
Bleeding
Hematoma

Physician-Ordered Bedrest
≤ 8 hours
> 8 hours
N = 22
73% N = 8
27%
3
14%
2
25%
1
4.5%
0
0

Actual Bedrest
≤ 8 hours
> 8 hours
N = 15
50% N = 15
50%
0
0
5
33%
1
6.7%
0
0

difficulty requiring catheterization, hematuria frequency, urgency, and pain and back pain while
on bedrest. Four patients had urinary complaints: 3 patients on physician-ordered shortened
bedrest track, and 1 on prolonged track. Only one patient with a urinary complaint was actually
in bed for 8 hours or less (M = 11; SD = 3.1). Three patients required urinary catheterization (1
with shortened bedrest; 2 with prolonged bedrest) and one patient had burning (prolonged
bedrest) with first urination that resolved spontaneously.
Table 4.3
Secondary Outcomes by Physician-Ordered Bedrest and Actual Time in Bed
Complication
Urinary
Complaints
Catheterization
Back Pain

Physician-Ordered Bedrest
Actual Bedrest
≤ 8 hours
> 8 hours
≤ 8 hours
> 8 hours
N= 22
73%
N= 8
27% N = 15
50% N =15
50%
2
9%
2
25%
1
6.7%
4 26.7%
2
10

9%
45%

2
0

25%
0

1
8

6.7%
53.3%

3
2

20%
13.3%

Ten patients of the entire sample complained of back pain while on bedrest and were all
physician ordered to be on the shortened bedrest track. Two patients were actually in bed longer
than 8 hours (M = 8.8; SD = 1.8). Three patients suffered from chronic back pain, 5 patients
rated their pain on a Likert scale from 3/10 to 10/10 and 5 patients had no pain scale rating
recorded. One patient required IV narcotics and the remaining patients were treated with oral
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medications, repositioning, and ambulation. One patient complaining of back pain remained in
bed for 14 hours at the nurse's recommendation.
Associations between Actual Bedrest Duration and Outcomes
Fisher’s Exact test showed no statistically significant difference in bleeding outcomes by
actual bedrest duration group (p= 0.39), gender (p= 0.56) or specific NOAC (p=0.27). Similarly,
the Wilcoxon rank sum found no significant difference in bleeding by age (p=0.65), or BMI
(p=0.7).
Fishers' Exact test showed no statistically significant difference in back pain outcomes by
gender (p= 0.66) or NOAC (p=1.0). Similarly, the Wilcoxon rank sum test found no statistically
significant difference in back pain by age (p=0.28) or BMI (p=0.96). There was near statistically
significant difference in back pain by actual time in bed (p= 0.07). Fishers' Exact test showed no
statistical significant difference in urinary complaints by specific NOAC (p= 1.0), and Wilcoxon
rank sum showed no statistical difference on absolute time in bed (p=0.46).
Summary
This study was small and underpowered yet is the beginning of gathering data about
outcomes of bleeding, urinary complaints, and back pain on patients undergoing AFCA on
NOACs. There was no statistically significant advantage to prolonged bedrest duration related to
bleeding. No adverse events were recorded with the shortened bedrest patients in the immediate
post-operative times, and bleeding occurred almost equally in both tracks of patients. There was
no clear advantage to shortened bedrest in terms of back pain or urinary complaints.
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Chapter V: Discussion
Bedrest duration following AFCA is variable and evidence is lacking for the optimal time
needed to minimize bleeding complications. The question is further compounded by the periprocedural use of NOACs and limited knowledge exists on potential bleeding complications.
This project to evaluate bedrest duration and bleeding among AFCA patients taking NOACs was
undertaken to add to the lacking body of evidence to guide best nursing practice. The goal was to
compare bleeding differences based on bedrest duration following the procedure. This chapter
presents a discussion of the findings of this project in the context of previous evidence and a
delineation of the limitations of the project. This is followed by identification of implications for
clinical practice and for future research.
Relation to Other Evidence
The literature review found no evidence to support an established amount of bedrest in
the AFCA patient population, but a plethora of high-level research in a similar population of
cardiac catheterization and PCI patients with progressively shortened bedrest duration was
reviewed. The existing research was exhaustive and conclusive that shortened bedrest duration
from over 12 hours reduced to less than 4 hours, was safe and efficacious following both DCC
and PCI procedures with femoral vascular access (Chair et al., 2008; Kim et al., 2013;
Mohammady et al., 2013; Tongsai & Thamlikithul, 2012). In similarity to prior research, the
current study, comparing 8 hours to longer than 8 hours showed no difference in bleeding
outcomes with shortened bedrest. The 8 hour timeframe was studied based on performing
physician preference of post procedure care. The literature on early ambulation in DCC and PCI
patients has been evolutionary and the current study begins the body of knowledge necessary to
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investigate bedrest duration and bleeding in the AFCA patient population (Keeling et al., 1994;
Keeling et al., 1996; Keeling et al., 2000; Reynolds et al., 2003; Searle & Hoff, 2000; Vaught &
Ostrow, 2001).
Similarly, the current study results were not statistically significant for urinary complaints
related to bedrest duration as in prior research (Chair et al., 2012). In the current study, urinary
complaints were present almost equally in the shortened and prolonged bedrest track patients.
Back pain was statistically significant in the physician-ordered shortened bedrest track patients in
the current study, and near statistical significance based on actual time in bed. Back pain was the
most common complaint reported among all patients, similar to previous research (Chair et al.,
2012; Gianakos et al., 2004).
One difference among the procedures is that DCC and PCI access involves a femoral
artery access with AFCA requiring femoral venous access. Both procedures are cared for pre
and post by the same nursing staff in the same catherization lab holding area. Femoral access
vascular hemostasis is achieved similarly following sheath removal with the same general
bedrest, limb immobilization, and limitations of head of bed elevation restrictions on both sets of
patients. Both procedures may require anticoagulation peri-procedurally, thus increasing the risk
of bleeding.
There was no statistically significant advantage to prolonged bedrest duration related to
bleeding. No adverse events were recorded with the shortened bedrest patients in the immediate
post-operative times, and bleeding occurred almost equally in both tracks of patients. There was
no clear advantage to shortened bedrest in terms of back pain or urinary complaints.
Limitations
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The sample size is small (n=30) and the results are not generalizable, but adequate to
portray clinical practice at this particular facility and are representative of the population
undergoing the procedure at this hospital. There are many possible confounding variables with
this study, including use of IV unfractionated heparin in varying doses, sheath size, physician
technique, procedure duration time, number of prior femoral vascular access procedures, and
varying times of medication administration peri-procedurally. Other confounding variables may
include patient characteristics of age, gender, chronic back pain, and BMI.
Defining bleeding and hematoma consistently was a limitation of the study. With
multiple NPs, nurses, and cath lab staff involved in caring for these patients, the perception and
definition of bleeding was variable. A valid and reliable hematoma measurement tool was
lacking and reliance upon accurate measurement by the nurse or NP was required in this study.
Also, bleeding outcome could be better quantified to determine if it was significant to require
additional bedrest. Bleeding is a subjective nurse measurement and some nurses viewed any
blood on the dressing, even if dried, as a reason to postpone patient ambulation.
A perception of bleeding complications with patients on NOACs continues to be
prevalent in this facility. In some cases, nursing would lengthen the bedrest duration based on
their beliefs. The time of the procedure also likely affected the time of ambulation. Often, the
patient would be allowed out of bed at midnight but would choose to sleep through until the
morning.
Pain assessment and measurements were also variable and lacking in detail. Some nurses
recorded the pain complaints, scales to assess, treatments, and responses to treatment, and others
were not clearly recorded or were lacking details. Due to the nature of the procedure and the
positioning required, many back pain complaints may have been overreported. Similar problems
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existed for recording urinary complaints and treatments. There was not a clear way to report and
record urinary complaints and treatments.
Implications for Practice
The findings support the hypothesis that shorter, or traditional bedrest duration of 8
hours, compared to prolonged bedrest of 12 hours or longer, did not increase bleeding
complications. These findings are useful in guiding nursing practice in caring for the patients
post procedurally. A standardized, post AFCA bedrest duration of 8 hours is sufficient to
maintain hemostasis in patients on NOACs. There was no benefit to maintain bedrest longer than
8 hours to minimize bleeding complications in this study sample. There was no less reported
back pain in the shortened back pain track and urinary complaints were similar in both groups.
The implications for nursing practice are important in changing practice in our institution
to a standard of post procedure AFCA bedrest duration care. The results represent hard data that
lengthened bedrest does not change the bleeding outcomes in this patient population. This data
collection will be continued through the year and further analyzed by the stakeholders to
collectively determine a standard of care. The findings will be submitted for presentation at the
annual Heart Rhythm Society in May 2015 and submitted for publication in electrophysiology
nursing literature.
Implications for Research
The implications for research include the need for well-designed randomized controlled
trials to evaluate well-defined variables in the AFCA patient population and the amount of
bedrest duration needed to minimize bleeding complications. This QI project should be the
beginning of further research to evaluate post procedure bedrest duration in AFCA patients on
NOACs. Future research may further analyze the role of intra-procedural use and amounts of
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unfractionated heparin, femoral access sheath sizes, patient characteristics of age, gender, BMI,
and chronic back pain. A reliable and validated bleeding and hematoma measurement tool would
be useful to quantify bleeding. Consistent use of a Likert pain scale for back pain would help
measure this outcome more accurately. Assessment of treatment response to interventions of
back pain should also be measured. Further interventions to minimize back pain in all post
operative AFCA patients should be investigated in future research, as this problem was more
common in shorter bedrest durations. Clear orders of bedrest duration tracks should be
standardized to minimize confusion among nursing and provider staff with sufficient and
ongoing education to ensure understanding.
Conclusion
The most important finding in this QI project was identification of the lack of evidence
on bedrest duration following the AFCA. The project further studied the population of patients
taking NOACs, as these drugs are quickly replacing the use of warfarin. With the increasing
prevalence of AF and the widely performed AFCA as a viable treatment option, nursing practice
must strive to offer evidence based care of these patients. As the AFCA procedure continues to
evolve with increased use of NOACs, smaller vascular access sheath sizes, shorter procedure
times, and more experienced operators, nursing care must be challenged to provide the best care
of these patients. As bedrest duration has shortened over decades in the DCC and PCI patient
populations while maintaining safe practice, it is hoped that the same may occur with AFCA
patients.
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Appendix A
Procedure Checklist
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Appendix B
Patient Measurement Outcomes
Question

Y

N

Describe

Did pt have rebleed requiring add'l bedrest?
Hematoma formation larger than 5 cm?
Was add'l testing, blood transfusion, or surgical consult
required?
Did pt complain of back pain while on bedrest restriction?
-1-10 Pain scale to describe most severe pain
Did patient have complaints of urinary burning, frequency,
bleeding, inability to void, and/or reinsertion of urinary
catheter
ACTUAL TIME OF AMBULATION_________________________
PATIENT BMI__________
ADDITIONAL COMMENTS______________________________________
CATH LAB STAFF: PLEASE ATTACH TO EP/CATH LAB HANDOFF SHEET (PURPLE
WORKSHEET) AND INCLUDE WHEN PT TRANSFERS TO FLOOR
FLOOR NURSING STAFF: PLEASE GIVE THIS SHEET TO CARDIOLOGY ARNP DAY
OF DISCHARGE OR PLACE IN COLLECTION BIN AT 2N NURSING STATION

QUESTIONS PLEASE DIRECT TO: LYNN MCWHIRTER, PI –ORCO-INVESTIGATORS: Not a part of permanent patient record

Patient label

Date
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Appendix C
NP QI Project Training
Novel Oral Anticoagulants: Bedrest and Bleeding in Patients Undergoing
Atrial Fibrillation Catheter Ablation
No change in practice is required for this project.
-Physician 1 patients will continue on standard post-procedure protocol of bedrest until
FemoStop pressure is completed at 8 hours following femoral vascular access hemostasis.
-Physician 2 patients will remain on bedrest an additional 4 hours following FemoStop pressure
completion for a minimum of 12 hours.
1) Enroll patients undergoing AFCA on NOACs for inclusion into project-no informed consent
required
a) Exclusion criteria:
-Difficult vascular access reported by physician
-Rebleeding or hematoma prior to transfer to floor as reported by nursing staff
2) Collect purple EP worksheet and 2nd page questionnaire at time of discharge
3) Review questions and answer/complete from review of chart
4) Place forms in "labeled collection bin" in PI file cabinet
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Appendix D
Nursing Staff Information

AFib Ablation Patients Bedrest Duration Study
Of Patients on Novel Oral Anticoagulants
(Dabigatran, Rivaroxaban, Apixaban)
 Study purpose
o To standardize post afib ablation bedrest
o Evaluate bleeding outcomes in different bedrest durations among afib
ablation pts on NOACs
o 3 month study: Feb, March, April
o Secondary measurements: Back pain, urinary complaints
 Usual care of patients
o Physician A patients remain on bedrest for 8 hours following sheath
removal and hemostasis
o Physician B patients remain on bedrest for 12 hours following sheath
removal and hemostasis
 Please write time patient ambulated OOB on handoff worksheet
 Additional questions to be asked at time of discharge and recorded on attached
sheet
o Did pt have rebleed requiring add’l bedrest?
o Did pt have hematoma >5 cm?
o Was add’l testing, blood transfusion, or surgical consult required?
o Did pt complain of back pain while on bedrest restriction?
 Use 1-10 VAS Scale to rate
o Did pt have urinary complaints: inability to void, require I&O cath, burning,
frequency, bleeding?
 Please save purple handoff sheets and questions/answers in bin at 2N A nursing
station for collection or give to a study investigator
 PI
Co-Investigators:
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Appendix E
Oral Consent Script
Protocol Title: Novel oral anticoagulants: Bedrest duration and bleeding among atrial fibrillation
ablation patients
IRB #:XXXXXX
Principal Investigator: XXXXXXX
You are being asked to participate in a research study about bleeding outcomes, back pain, and
urinary complaints in atrial fibrillation ablation patients taking novel oral anticoagulation.
If you agree to participate you will be asked to answer simple questions about back pain and
urinary complaints. Your age, gender, and body mass index will be recorded as well as your
answers to the questions. If you had bleeding from your access sites, this will be recorded. We
will not link the information to your identity and you will remain anonymous. You will not
receive payment for your participation.
The risks associated with the research study are not increased. These are the questions we would
ask if you are not included in this study project. Your care will remain the same whether you are
in the study or not. There should not be an increase in your time, discomfort, or confidentiality if
you agree to participate.
The benefits which may reasonably be expected to result from this research study will not
directly affect your stay but it is hoped to streamline care in the future
Please understand your participation is voluntary and you have the right to withdraw your
consent or discontinue participation at any time without penalty. Specifically, your current or
future medical care at the XXXX will not be jeopardized if you choose not to participate.
If you have any questions about this research study you can contact me at 555-5555. If you have
any concerns, complaints, or general questions about research or your rights as a participant,
please contact the XXX Institutional Review Board (IRB) to speak to someone independent of
the research team at 555-555-55555 or toll free at 555-555-5555.
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